Human Anti-GXM Recombinant Antibody (clone G15) (CAT#: FAMAB-0562WJ)

Figure 1 Binding of MAbs G14, G15, and G19 to serotype A and D GXMs.

(A, B, and C) Binding of MAbs to purified GXM from strains 24067, SB4, and H99, respectively. (D, E, and F) Binding of MAbs to heat-killed whole cells from strains 24067, SB4, and H99, respectively. Binding is represented by the absorbance at 405 nm (Abs405) as shown on the y axis for the amount of the indicated MAb on the x axis.

Maitta, R. W., Datta, K., Chang, Q., Luo, R. X., Witover, B., Subramaniam, K., & Pirofski, L. A. (2004). Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infection and immunity, 72(8), 4810-4818.

Figure 2 Inhibition of G14, G15, and G19 binding by soluble serotype A and D GXMs.

Binding by ELISA is shown. (A) Inhibition of the binding of the MAbs to 24067 by soluble SB4;

Maitta, R. W., Datta, K., Chang, Q., Luo, R. X., Witover, B., Subramaniam, K., & Pirofski, L. A. (2004). Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infection and immunity, 72(8), 4810-4818.

Figure 3 Inhibition of G14, G15, and G19 binding by soluble serotype A and D GXMs.

Binding by ELISA is shown. (B) inhibition of the binding of the MAbs to 24067 by soluble 24067;

Maitta, R. W., Datta, K., Chang, Q., Luo, R. X., Witover, B., Subramaniam, K., & Pirofski, L. A. (2004). Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infection and immunity, 72(8), 4810-4818.

Figure 4 Inhibition of G14, G15, and G19 binding by soluble serotype A and D GXMs.

Binding by ELISA is shown. (C) inhibition of the binding of the MAbs to H99 by soluble SB4. Binding is represented by the absorbance at 405 nm (Abs405) as shown on the y axis for the concentration of the indicated soluble GXM on the x axis. The curve representing G15 in panel A is not seen because it is the same as that of the control IgM.

Maitta, R. W., Datta, K., Chang, Q., Luo, R. X., Witover, B., Subramaniam, K., & Pirofski, L. A. (2004). Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infection and immunity, 72(8), 4810-4818.

Figure 5 Immunofluorescent staining of C. neoformans serotype D (strain 24067) with GXM MAbs G14, G15, and G19.

Staining was performed as detailed in the text with anti-human IgM rhodamine to detect MAb binding and Calcofluor white to detect the cell wall. The top panels show the immunofluorescent image, and the bottom panels show the phase image of the corresponding MAb shown in the upper panels. Magnification, ×100.

Maitta, R. W., Datta, K., Chang, Q., Luo, R. X., Witover, B., Subramaniam, K., & Pirofski, L. A. (2004). Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infection and immunity, 72(8), 4810-4818.

Figure 6 Survival of BALB/c mice treated with G14, G15, or G19 after challenge with C. neoformans strain 24067.

MAb treatment and C. neoformans challenge were performed i.p. (A) Survival of mice given 1 mg of the MAbs per mouse; (B) survival of mice given 100 μg of the MAbs per mouse; (C) survival of mice given 50 μg of the MAbs per mouse; (D) survival of mice given 5 μg of the MAbs per mouse. In each panel, the y axis represents the percentage of surviving mice, and the x axis depicts the number of days after i.p. infection (n = 10 mice/group; *, P < 0.04 [Kaplan-Meier log rank survival]).

Maitta, R. W., Datta, K., Chang, Q., Luo, R. X., Witover, B., Subramaniam, K., & Pirofski, L. A. (2004). Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infection and immunity, 72(8), 4810-4818.